Readoutin 14d
Boehringer Ingelheim — BI 690517
Phase 3 primary completion: EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin).
- Date
- Dec 2026
- Type
- Readout
- Indication
- Kidney Disease, Chronic
Readoutin 14d
Phase 3 primary completion: EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin).
The weekly brief is free. Pro adds reminders 7 days and 1 day before.